Helena T Hogberg, Ellen Fritsche, Sibylle Gröters, Ramesh C Kovi, Deepa B Rao, Andrea Terron, Matthew J Winter
{"title":"2024国际毒理学病理学会(IATP)卫星研讨会:神经毒性评估和监管前景的新方法方法(NAMs)。","authors":"Helena T Hogberg, Ellen Fritsche, Sibylle Gröters, Ramesh C Kovi, Deepa B Rao, Andrea Terron, Matthew J Winter","doi":"10.1177/01926233251335719","DOIUrl":null,"url":null,"abstract":"<p><p>The International Academy of Toxicologic Pathology (IATP) Satellite Symposium on \"New Approach Methodologies (NAMs) for Neurotoxicity Assessment and Regulatory Perspectives,\" organized in Spain, addressed the growing need for improved assessment of neurotoxicity. Traditional neurotoxicity assessment using in vivo animal studies are impractical for testing the substantial number of environmental chemicals that currently lack data and in the early detection of neuro-related adverse reactions in drug discovery. The NAMs, including human in vitro assays and small model organisms, have been developed for faster and cost-effective assessment of neurotoxic potential. While NAMs offer improved practicality, utility, and valuable mechanistic insights, their integration into regulatory decision-making requires robust scientific validation and technical characterization. Confidence in and regulatory application of NAMs data can be supported by mapping cellular outcomes to neuropathological findings in mammals, including humans, through the Adverse Outcome Pathway (AOP) framework, and the Integrated Approach to Testing and Assessment (IATA). Case studies presented demonstrated the application of NAMs in chemical and drug safety evaluations, focusing on developmental neurotoxicity (DNT), Parkinson's disease, and drug-induced seizures. In conjunction with in vivo toxicology studies, NAMs represent a significant step toward advancing chemical and drug toxicity assessment via hazard identification and drug screening safety assessments.</p>","PeriodicalId":23113,"journal":{"name":"Toxicologic Pathology","volume":" ","pages":"1926233251335719"},"PeriodicalIF":1.4000,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"2024 International Academy of Toxicologic Pathology (IATP) Satellite Symposium: New Approach Methodologies (NAMs) for Neurotoxicity Assessment and Regulatory Perspectives.\",\"authors\":\"Helena T Hogberg, Ellen Fritsche, Sibylle Gröters, Ramesh C Kovi, Deepa B Rao, Andrea Terron, Matthew J Winter\",\"doi\":\"10.1177/01926233251335719\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The International Academy of Toxicologic Pathology (IATP) Satellite Symposium on \\\"New Approach Methodologies (NAMs) for Neurotoxicity Assessment and Regulatory Perspectives,\\\" organized in Spain, addressed the growing need for improved assessment of neurotoxicity. Traditional neurotoxicity assessment using in vivo animal studies are impractical for testing the substantial number of environmental chemicals that currently lack data and in the early detection of neuro-related adverse reactions in drug discovery. The NAMs, including human in vitro assays and small model organisms, have been developed for faster and cost-effective assessment of neurotoxic potential. While NAMs offer improved practicality, utility, and valuable mechanistic insights, their integration into regulatory decision-making requires robust scientific validation and technical characterization. Confidence in and regulatory application of NAMs data can be supported by mapping cellular outcomes to neuropathological findings in mammals, including humans, through the Adverse Outcome Pathway (AOP) framework, and the Integrated Approach to Testing and Assessment (IATA). Case studies presented demonstrated the application of NAMs in chemical and drug safety evaluations, focusing on developmental neurotoxicity (DNT), Parkinson's disease, and drug-induced seizures. In conjunction with in vivo toxicology studies, NAMs represent a significant step toward advancing chemical and drug toxicity assessment via hazard identification and drug screening safety assessments.</p>\",\"PeriodicalId\":23113,\"journal\":{\"name\":\"Toxicologic Pathology\",\"volume\":\" \",\"pages\":\"1926233251335719\"},\"PeriodicalIF\":1.4000,\"publicationDate\":\"2025-05-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Toxicologic Pathology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/01926233251335719\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"PATHOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Toxicologic Pathology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/01926233251335719","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PATHOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
国际毒理学病理学会(IATP)卫星研讨会“神经毒性评估和监管视角的新方法(NAMs)”在西班牙举办,讨论了对改进神经毒性评估的日益增长的需求。传统的使用活体动物研究的神经毒性评估对于目前缺乏数据的大量环境化学物质的测试和药物发现中神经相关不良反应的早期检测是不切实际的。NAMs,包括人类体外试验和小型模式生物,已经开发出更快和具有成本效益的神经毒性潜在评估。虽然NAMs提供了改进的实用性、实用性和有价值的机制见解,但将其集成到监管决策中需要强有力的科学验证和技术表征。通过Adverse Outcome Pathway (AOP)框架和Integrated Approach to Testing and Assessment (IATA),将细胞结果映射到哺乳动物(包括人类)的神经病理结果,可以支持对NAMs数据的信心和监管应用。案例研究展示了NAMs在化学和药物安全性评估中的应用,重点是发育性神经毒性(DNT)、帕金森病和药物性癫痫发作。与体内毒理学研究相结合,NAMs代表了通过危险识别和药物筛选安全性评估来推进化学和药物毒性评估的重要一步。
2024 International Academy of Toxicologic Pathology (IATP) Satellite Symposium: New Approach Methodologies (NAMs) for Neurotoxicity Assessment and Regulatory Perspectives.
The International Academy of Toxicologic Pathology (IATP) Satellite Symposium on "New Approach Methodologies (NAMs) for Neurotoxicity Assessment and Regulatory Perspectives," organized in Spain, addressed the growing need for improved assessment of neurotoxicity. Traditional neurotoxicity assessment using in vivo animal studies are impractical for testing the substantial number of environmental chemicals that currently lack data and in the early detection of neuro-related adverse reactions in drug discovery. The NAMs, including human in vitro assays and small model organisms, have been developed for faster and cost-effective assessment of neurotoxic potential. While NAMs offer improved practicality, utility, and valuable mechanistic insights, their integration into regulatory decision-making requires robust scientific validation and technical characterization. Confidence in and regulatory application of NAMs data can be supported by mapping cellular outcomes to neuropathological findings in mammals, including humans, through the Adverse Outcome Pathway (AOP) framework, and the Integrated Approach to Testing and Assessment (IATA). Case studies presented demonstrated the application of NAMs in chemical and drug safety evaluations, focusing on developmental neurotoxicity (DNT), Parkinson's disease, and drug-induced seizures. In conjunction with in vivo toxicology studies, NAMs represent a significant step toward advancing chemical and drug toxicity assessment via hazard identification and drug screening safety assessments.
期刊介绍:
Toxicologic Pathology is dedicated to the promotion of human, animal, and environmental health through the dissemination of knowledge, techniques, and guidelines to enhance the understanding and practice of toxicologic pathology. Toxicologic Pathology, the official journal of the Society of Toxicologic Pathology, will publish Original Research Articles, Symposium Articles, Review Articles, Meeting Reports, New Techniques, and Position Papers that are relevant to toxicologic pathology.